Literature DB >> 30089587

EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC).

Cecilia Pompili1, Michael Koller2, Galina Velikova3, Kevin Franks4, Kate Absolom3, Matthew Callister5, Jonathan Robson5, Andrea Imperatori6, Alessandro Brunelli6.   

Abstract

INTRODUCTION: We tested the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) summary score (SumSC) to detect changes in the HRQOL after Non-small-cell lung cancer (NSCLC) surgery and compared its performance to the traditional scales.
METHOD: EORTC QLQ-C30 data was obtained from 326 consecutive pre-operative patients submitted for anatomical lung resections for NSCLC.66 patients completed post-operative assessments 3 months after surgery. The data was analysed to evaluate the ability of the SumSC compared to the traditional scales to [1] preoperatively differentiate between clinical groups [2]; detect post-op changes and to [3] compare pre and post-op changes in clinically different groups.The importance of perioperative changes was measured by calculating the effect size (ES).
RESULTS: Of the 326 patients, those older than 70 years, with higher DLCO value and Performance Status (PS) ≤1 had a significantly better preoperative SumScore. Physical function (PF) showed a large and significant decline (ES 0.91). Role and social function also showed a significant and medium decline (ES 0.62 and 0.41). Postoperatively some symptoms scales showed significant increases in the values, implying worse symptoms with the largest increase in dyspnoea (ES -0.88). The change in General Health score (GH) was not significant after surgery (ES 0.26, p = 0.062). The SumSc, decreased significantly postoperatively. In particular, medium or large postoperative declines of SumSc were observed in both males and females, in patients with lower FEV1, lower performance score, and in those older than 70 years. Interestingly the decline of SumSc was observed irrespective of the preoperative DLCO level. DISCUSSION: The Summary Score was more sensitive to changes in subjects' HRQOL, than the GH score. The SumSc can be used as a parsimonious and easy to interpreted patient-reported-outcome measure in multi-institutional database and future clinical trials.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lobectomy; Lung cancer surgery; Patient-reported outcomes; Quality of life; Summary score

Mesh:

Year:  2018        PMID: 30089587     DOI: 10.1016/j.lungcan.2018.07.021

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  16 in total

Review 1.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 2: systematic review of evidence regarding resection extent in generally healthy patients.

Authors:  Frank C Detterbeck; Vincent J Mase; Andrew X Li; Ulas Kumbasar; Brett C Bade; Henry S Park; Roy H Decker; David C Madoff; Gavitt A Woodard; Whitney S Brandt; Justin D Blasberg
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

2.  Effects of curative-intent lung cancer therapy on functional exercise capacity and patient-reported outcomes.

Authors:  Duc Ha; Andrew L Ries; Scott M Lippman; Mark M Fuster
Journal:  Support Care Cancer       Date:  2020-01-21       Impact factor: 3.603

3.  Dimensionality and Measurement Invariance of the Italian Version of the EORTC QLQ-C30 in Postoperative Lung Cancer Patients.

Authors:  Chiara Marzorati; Dario Monzani; Ketti Mazzocco; Francesca Pavan; Massimo Monturano; Gabriella Pravettoni
Journal:  Front Psychol       Date:  2019-10-08

4.  "Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study".

Authors:  Brett C Bade; Geliang Gan; Fangyong Li; Lingeng Lu; Lynn Tanoue; Gerard A Silvestri; Melinda L Irwin
Journal:  BMC Cancer       Date:  2021-04-01       Impact factor: 4.430

5.  Symptom trajectories during chemotherapy in patients with non-small cell lung cancer (NSCLC) and the function of prolonging low dose dexamethasone in promoting enhanced recovery after chemotherapy.

Authors:  Jinghao Liu; Xingyu Liu; Ming Dong; Honglin Zhao; Mei Li; Hongbing Zhang; Huihui Ji; Yi Shi; Yajie Cui; Di Wu; Gang Chen; Jun Chen
Journal:  Thorac Cancer       Date:  2021-01-25       Impact factor: 3.500

6.  Preoperative predictors of restoration in quality of life after surgery for lung cancer.

Authors:  Hideo Ichimura; Keisuke Kobayashi; Masahiko Gosho; Kojiro Nakaoka; Takahiro Yanagihara; Sho Ueda; Yusuke Saeki; Naoki Maki; Naohiro Kobayashi; Shinji Kikuchi; Hisashi Suzuki; Yukinobu Goto; Yukio Sato
Journal:  Thorac Cancer       Date:  2021-01-28       Impact factor: 3.500

Review 7.  Choosing the right survey: the lung cancer surgery.

Authors:  Cecilia Pompili; Michael Koller; Galina Velikova
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

8.  Impact on quality of life after vagus nerve and phrenic nerve guided systematic nodal dissection for non-small cell lung cancer patients: a prospective, single-arm clinical trial.

Authors:  Yao Liu; Weixiong Yang; Jiali Yang; Shufen Liao; Zhenguo Liu; Bo Zeng; Chao Cheng
Journal:  Ann Transl Med       Date:  2021-12

9.  Increases in adipose tissue and muscle function are longitudinally associated with better quality of life in colorectal cancer survivors.

Authors:  Marlou-Floor Kenkhuis; Eline H van Roekel; Janna L Koole; José J L Breedveld-Peters; Stéphanie O Breukink; Maryska L G Janssen-Heijnen; Eric T P Keulen; Fränzel J B van Duijnhoven; Floortje Mols; Matty P Weijenberg; Martijn J L Bours
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

10.  Development and Validation of a Symptom-Focused Quality of Life Questionnaire (KOQUSS-40) for Gastric Cancer Patients after Gastrectomy.

Authors:  Bang Wool Eom; Joongyub Lee; In Seob Lee; Young-Gil Son; Keun Won Ryu; Sung Geun Kim; Hyoung-Il Kim; Young-Woo Kim; Seong-Ho Kong; Oh Kyoung Kwon; Ji-Ho Park; Ji Yeong An; Chang Hyun Kim; Byoung-Jo Suh; Hong Man Yoon; Myoung Won Son; Ji Yeon Park; Jong-Min Park; Sang-Ho Jeong; Moon-Won Yoo; Geum Jong Song; Han-Kwang Yang; Yun-Suhk Suh; Ki Bum Park; Sang-Hoon Ahn; Dong Woo Shin; Ye Seob Jee; Hye-Seong Ahn; Sol Lee; Jae Seok Min; Haejin In; Ahyoung Kim; Hoon Hur; Hyuk-Joon Lee
Journal:  Cancer Res Treat       Date:  2020-12-29       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.